PT1237551E - PHARMACEUTICAL FORMULATIONS CONTAINING ZOLMITRIPTAN - Google Patents

PHARMACEUTICAL FORMULATIONS CONTAINING ZOLMITRIPTAN

Info

Publication number
PT1237551E
PT1237551E PT00979765T PT00979765T PT1237551E PT 1237551 E PT1237551 E PT 1237551E PT 00979765 T PT00979765 T PT 00979765T PT 00979765 T PT00979765 T PT 00979765T PT 1237551 E PT1237551 E PT 1237551E
Authority
PT
Portugal
Prior art keywords
pharmaceutical formulations
formulations containing
zolmitriptan
containing zolmitriptan
formulation
Prior art date
Application number
PT00979765T
Other languages
Portuguese (pt)
Inventor
Dearn Alan Roy
Williamson Sarah Louise
Summers Simon John
Coomber Trevor John
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1237551(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1237551E publication Critical patent/PT1237551E/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Abstract

A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
PT00979765T 1999-12-03 2000-11-28 PHARMACEUTICAL FORMULATIONS CONTAINING ZOLMITRIPTAN PT1237551E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
PT1237551E true PT1237551E (en) 2005-07-29

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00979765T PT1237551E (en) 1999-12-03 2000-11-28 PHARMACEUTICAL FORMULATIONS CONTAINING ZOLMITRIPTAN

Country Status (28)

Country Link
US (2) US6750237B1 (en)
EP (1) EP1237551B1 (en)
JP (1) JP2003515559A (en)
KR (1) KR100670092B1 (en)
CN (1) CN1222287C (en)
AT (1) ATE291914T1 (en)
AU (1) AU778092B2 (en)
BR (1) BRPI0016138B8 (en)
CA (1) CA2392050C (en)
CZ (1) CZ301528B6 (en)
DE (1) DE60019162T2 (en)
EE (1) EE05305B1 (en)
ES (1) ES2236001T3 (en)
GB (2) GB9928578D0 (en)
HK (3) HK1048442B (en)
HU (1) HU229458B1 (en)
IL (2) IL149578A0 (en)
IS (1) IS2135B (en)
MX (1) MXPA02005319A (en)
NO (1) NO322119B1 (en)
NZ (1) NZ518862A (en)
PL (1) PL200679B1 (en)
PT (1) PT1237551E (en)
RU (1) RU2255736C2 (en)
SK (1) SK287228B6 (en)
UA (1) UA75059C2 (en)
WO (1) WO2001039772A1 (en)
ZA (1) ZA200203704B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (en) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
CA2566384C (en) * 2004-05-28 2010-08-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2006055964A2 (en) * 2004-11-19 2006-05-26 Teva Pharmaceutical Industries Ltd. Zolmitriptan crystal forms
CN100341504C (en) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 Zolmitriptan quick-release formulation
EP3449928A1 (en) * 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
CA2666149A1 (en) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
KR101517415B1 (en) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant
WO2012048710A1 (en) 2010-10-15 2012-04-19 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
JP6121734B2 (en) * 2012-02-09 2017-04-26 久光製薬株式会社 Zolmitriptan-containing coating composition for microneedles and microneedle device
MX361372B (en) 2012-04-18 2018-12-05 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders.
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (en) 2014-10-29 2016-05-24 연세대학교 산학협력단 The pharmaceutical composition of increasing solubility by using saccharin
EP3310360B1 (en) * 2015-06-19 2024-03-27 Beijing Artivila BioPharma Co. Ltd. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
TW201932107A (en) * 2017-12-21 2019-08-16 台灣微脂體股份有限公司 Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114690A (en) 1990-06-07 1997-02-18 Wellcome Found Antimigraine oxazolidinone substituted indole derivatives
CA2259418A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
JP2001511160A (en) 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト Aerosol formulation for medical use
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
BR0016138B1 (en) 2013-09-10
KR20020058051A (en) 2002-07-12
ZA200203704B (en) 2003-10-29
BRPI0016138B8 (en) 2021-05-25
HUP0203597A2 (en) 2003-02-28
RU2255736C2 (en) 2005-07-10
DE60019162D1 (en) 2005-05-04
GB9928578D0 (en) 2000-02-02
UA75059C2 (en) 2006-03-15
CA2392050A1 (en) 2001-06-07
MXPA02005319A (en) 2002-12-06
GB0214845D0 (en) 2002-08-07
NO20022525L (en) 2002-05-28
SK7532002A3 (en) 2002-12-03
SK287228B6 (en) 2010-03-08
EE200200283A (en) 2003-06-16
HK1048442A1 (en) 2003-04-04
ATE291914T1 (en) 2005-04-15
CA2392050C (en) 2009-11-24
KR100670092B1 (en) 2007-01-17
EP1237551A1 (en) 2002-09-11
US6750237B1 (en) 2004-06-15
GB2373726A (en) 2002-10-02
CN1222287C (en) 2005-10-12
NO322119B1 (en) 2006-08-14
WO2001039772A1 (en) 2001-06-07
PL200679B1 (en) 2009-01-30
AU778092B2 (en) 2004-11-18
NO20022525D0 (en) 2002-05-28
US7220767B2 (en) 2007-05-22
CN1402636A (en) 2003-03-12
HK1048445A1 (en) 2003-04-04
PL357597A1 (en) 2004-07-26
HK1053430A1 (en) 2003-10-24
EP1237551B1 (en) 2005-03-30
CZ20021901A3 (en) 2002-11-13
IL149578A (en) 2008-04-13
IL149578A0 (en) 2002-11-10
DE60019162T2 (en) 2006-02-02
HUP0203597A3 (en) 2005-07-28
EE05305B1 (en) 2010-06-15
HU229458B1 (en) 2013-12-30
ES2236001T3 (en) 2005-07-16
HK1048445B (en) 2005-08-26
RU2002117649A (en) 2004-01-27
CZ301528B6 (en) 2010-04-07
GB2373726B (en) 2004-10-20
IS6394A (en) 2002-05-24
NZ518862A (en) 2004-02-27
AU1715701A (en) 2001-06-12
US20040214899A1 (en) 2004-10-28
JP2003515559A (en) 2003-05-07
HK1048442B (en) 2005-05-13
IS2135B (en) 2006-08-15
BR0016138A (en) 2002-08-06

Similar Documents

Publication Publication Date Title
PT1237551E (en) PHARMACEUTICAL FORMULATIONS CONTAINING ZOLMITRIPTAN
GB0005251D0 (en) Therapeutic compounds
TR199901417T2 (en) New compositions with analgesic effect.
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
ID27504A (en) NEW ORAL FORMULATION
TR199801180T2 (en) New compounds with analgesic effect.
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
RS50091B (en) Use of retigabine for the treatment of neuropathic pain
DK0907365T3 (en) Hitherto unknown formulation
HUP0301349A2 (en) Formulations for il-11
NO20004419D0 (en) New use
DK1112060T3 (en) Dosage form using liquid formulation
ATE301999T1 (en) DRY POWDER FORMULATION CONTAINING RACECADOTRIL
RS49599B (en) Use of h+, k+ -atpaze inhibitors and glucocortifoids and pharmaceutical formulation
SE0001916D0 (en) Novel formulation
TR199801184T2 (en) New compounds with analgesic action.
DE60121048D1 (en) PYRAZINOi1'2 ': 1,6öPYRIDOi3,4-BöINDOLDERIVATE
SE9604752D0 (en) Formulation and use
ES2159479A1 (en) Set of therapeutic indazols consists of inhibitors of cyclooxygenase combating eg. inflammation and Alzheimer's disease
TR200000916T2 (en) Substituted piperidine derivatives.
ATE247976T1 (en) 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE AS A THERAPEUTIC AGENT
UA38889A (en) LIVAREX MEDICINAL PRODUCT BASED ON DIMETHOXYUREIDOPHOSPHORIC ACID